OBJECTIVES: To determine whether noninvasive tests including the residual fraction are reliable for the diagnosis of bladder outlet obstruction (BOO). METHODS: A total of 212 men (median age 68, range 44-89 years) were included in the present study. The median serum prostate-specific antigen level and prostate volume were 1.3 ng/mL (range 0.2 to 9.4) and 37.9 mL (range 11.3 to 148.0), respectively. RESULTS: Among the variables analyzed in the multivariate model, the likelihood of BOO varied by the total prostate volume, with a 3.6-fold higher odds for >or=40 mL than for <40 mL (odds ratio [OR], 3.616; 95% confidence interval [CI], 1.217-10.749; P = 0.021). In the same model, a low maximal flow rate (Qmax) (OR, 2.840; 95% CI, 1.260-6.401; P = 0.012) and high residual fraction (OR, 7.103; 95% CI, 1.924-26.225; P = 0.003) were associated with an increased likelihood of BOO. The sensitivity and specificity for predicting BOO using a total prostate volume of 40 mL or greater were 73.7% and 65.2%, respectively. Using a Qmax cut-off of 12 mL/s or less for predicting BOO, the sensitivity and specificity were 77.2% and 54.2%, respectively. Prediction of the BOO by the residual fraction only had a sensitivity and specificity, for a residual fraction of less than 20%, of 75.4% and 67.7%, respectively. CONCLUSIONS: The presence or absence of BOO might be predicted using non-invasive methods. The residual fraction may help with patient management by better predicting the likely patient classification from pressure-flow studies.
OBJECTIVES: To determine whether noninvasive tests including the residual fraction are reliable for the diagnosis of bladder outlet obstruction (BOO). METHODS: A total of 212 men (median age 68, range 44-89 years) were included in the present study. The median serum prostate-specific antigen level and prostate volume were 1.3 ng/mL (range 0.2 to 9.4) and 37.9 mL (range 11.3 to 148.0), respectively. RESULTS: Among the variables analyzed in the multivariate model, the likelihood of BOO varied by the total prostate volume, with a 3.6-fold higher odds for >or=40 mL than for <40 mL (odds ratio [OR], 3.616; 95% confidence interval [CI], 1.217-10.749; P = 0.021). In the same model, a low maximal flow rate (Qmax) (OR, 2.840; 95% CI, 1.260-6.401; P = 0.012) and high residual fraction (OR, 7.103; 95% CI, 1.924-26.225; P = 0.003) were associated with an increased likelihood of BOO. The sensitivity and specificity for predicting BOO using a total prostate volume of 40 mL or greater were 73.7% and 65.2%, respectively. Using a Qmax cut-off of 12 mL/s or less for predicting BOO, the sensitivity and specificity were 77.2% and 54.2%, respectively. Prediction of the BOO by the residual fraction only had a sensitivity and specificity, for a residual fraction of less than 20%, of 75.4% and 67.7%, respectively. CONCLUSIONS: The presence or absence of BOO might be predicted using non-invasive methods. The residual fraction may help with patient management by better predicting the likely patient classification from pressure-flow studies.
Authors: Young Hwii Ko; Ji Yun Chae; Seung Min Jeong; Jae Il Kang; Hong Jae Ahn; Hyung Woo Kim; Sung Gu Kang; Hoon Ah Jang; Jun Cheon; Je Jong Kim; Jeong Gu Lee Journal: Int Neurourol J Date: 2010-12-31 Impact factor: 2.835